Gang Wu1,2, Weiyuan Huang3, Junnv Xu1,4, Wenzhu Li3, Yu Wu5, Qianyu Yang3, Kun Liu1, Mingyue Zhu1, Priya S Balasubramanian6, Mengsen Li7,8. 1. Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, Hainan Medical University, No. 3, Xueyuan Road, Longhua District, HaiKou, 571199, Hainan, People's Republic of China. 2. Department of Radiotherapy, Affiliated Hainan Hospital of Hainan Medical University (Hainan General Hospital), HaiKou, People's Republic of China. 3. Department of Radiology, Affiliated Hainan Hospital of Hainan Medical University (Hainan General Hospital), HaiKou, People's Republic of China. 4. Department of Medical Oncology, the Second Affiliated Hospital of Hainan Medical University, HaiKou, People's Republic of China. 5. Department of Pathology, Affiliated Hainan Hospital of Hainan Medical University (Hainan General Hospital), HaiKou, People's Republic of China. 6. Department of Electrical and Computer Engineering, Cornell University, Ithaca, USA. 7. Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, Hainan Medical University, No. 3, Xueyuan Road, Longhua District, HaiKou, 571199, Hainan, People's Republic of China. mengsenli@163.com. 8. Institution of Tumor, Hainan Medical University, No. 3, Xueyuan Road, Longhua District, HaiKou, 571199, Hainan, People's Republic of China. mengsenli@163.com.
Abstract
OBJECTIVES: The objective of our study was to investigate whether a phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression was associated with dynamic contrast-enhanced MRI (DCE-MRI) parameters and prognosis in nasopharyngeal carcinoma (NPC). METHODS: Two-hundred-and-forty-five (245) patients with NPC who underwent pretreatment biopsy, expression of PTEN detected by immunohistochemistry of biopsy, and radical intensity-modulated radiation therapy (IMRT) with or without chemotherapy were included. Tumor segmentations were delineated on pretreatment MRI manually. The pharmacokinetic parameters (Ktrans, Kep, Ve, and Vp) derived from dynamic contrast-enhanced MRI (DCE-MRI) using the extended Toft's model within the tumor segmentations were estimated. The following demographics and clinical features were assessed and correlated against each other: gender, age, TNM stage, clinical-stage, Epstein-Barr virus (EBV), pathological type, progression-free survival (PFS), and prognosis status. DCE parameter evaluation and clinical feature comparison between the PTEN positive and negative groups were performed and correlation between PTEN expression with the PFS and prognosis status using Cox regression for survival analysis were assessed. RESULTS: A significantly lower Ktrans and Kep were found in NPC tumors in PTEN negative patients than in PTEN positive patients. Ktrans performed better than Kep in detecting PTEN expression with the ROC AUC of 0.752. PTEN negative was associated with later TNM stage, later clinical-stage, shorter PFS, and worse prognosis. Moreover, N stage, pathological type, Kep, and prognostic status can be considered as independent variables in discrimination of PTEN negative expression in NPCs. CONCLUSIONS: PTEN negative indicated a shorter PFS and worse prognosis than PTEN positive in NPC patients. Ktrans and Kep derived from DCE-MRI, which yielded reliable capability, may be considered as potential imaging markers that are correlated with PTEN expression and could be used to predict PTEN expression noninvasively. Combined radiological and clinical features can improve the performance of the classification of PTEN expression.
OBJECTIVES: The objective of our study was to investigate whether a phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression was associated with dynamic contrast-enhanced MRI (DCE-MRI) parameters and prognosis in nasopharyngeal carcinoma (NPC). METHODS: Two-hundred-and-forty-five (245) patients with NPC who underwent pretreatment biopsy, expression of PTEN detected by immunohistochemistry of biopsy, and radical intensity-modulated radiation therapy (IMRT) with or without chemotherapy were included. Tumor segmentations were delineated on pretreatment MRI manually. The pharmacokinetic parameters (Ktrans, Kep, Ve, and Vp) derived from dynamic contrast-enhanced MRI (DCE-MRI) using the extended Toft's model within the tumor segmentations were estimated. The following demographics and clinical features were assessed and correlated against each other: gender, age, TNM stage, clinical-stage, Epstein-Barr virus (EBV), pathological type, progression-free survival (PFS), and prognosis status. DCE parameter evaluation and clinical feature comparison between the PTEN positive and negative groups were performed and correlation between PTEN expression with the PFS and prognosis status using Cox regression for survival analysis were assessed. RESULTS: A significantly lower Ktrans and Kep were found in NPC tumors in PTEN negative patients than in PTEN positive patients. Ktrans performed better than Kep in detecting PTEN expression with the ROC AUC of 0.752. PTEN negative was associated with later TNM stage, later clinical-stage, shorter PFS, and worse prognosis. Moreover, N stage, pathological type, Kep, and prognostic status can be considered as independent variables in discrimination of PTEN negative expression in NPCs. CONCLUSIONS: PTEN negative indicated a shorter PFS and worse prognosis than PTEN positive in NPC patients. Ktrans and Kep derived from DCE-MRI, which yielded reliable capability, may be considered as potential imaging markers that are correlated with PTEN expression and could be used to predict PTEN expression noninvasively. Combined radiological and clinical features can improve the performance of the classification of PTEN expression.
Authors: Alexander F DeVries; Christian Kremser; Patrick A Hein; Jürgen Griebel; Alfons Krezcy; Dietmar Ofner; Karl Peter Pfeiffer; Peter Lukas; Werner Judmaier Journal: Int J Radiat Oncol Biol Phys Date: 2003-07-15 Impact factor: 7.038
Authors: Alexandre A B A da Costa; Felipe D'Almeida Costa; Daniel Vilarim Araújo; Marcos Pedro Guedes Camandaroba; Victor Hugo Fonseca de Jesus; Audrey Oliveira; Ana Caroline Fonseca Alves; Carlos Stecca; Larissa Machado; Andrea Cruz Feraz de Oliveira; Thiago Bueno de Oliveira; Ulisses Ribaldo Nicolau; Vladmir Cláudio Cordeiro de Lima Journal: Med Oncol Date: 2018-11-26 Impact factor: 3.064
Authors: Stephanie B Donaldson; Guy Betts; Suzanne C Bonington; Jarrod J Homer; Nick J Slevin; Lucy E Kershaw; Helen Valentine; Catharine M L West; David L Buckley Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-04 Impact factor: 7.038
Authors: A Dimitrios Colevas; Sue S Yom; David G Pfister; Sharon Spencer; David Adelstein; Douglas Adkins; David M Brizel; Barbara Burtness; Paul M Busse; Jimmy J Caudell; Anthony J Cmelak; David W Eisele; Moon Fenton; Robert L Foote; Jill Gilbert; Maura L Gillison; Robert I Haddad; Wesley L Hicks; Ying J Hitchcock; Antonio Jimeno; Debra Leizman; Ellie Maghami; Loren K Mell; Bharat B Mittal; Harlan A Pinto; John A Ridge; James Rocco; Cristina P Rodriguez; Jatin P Shah; Randal S Weber; Matthew Witek; Frank Worden; Weining Zhen; Jennifer L Burns; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2018-05 Impact factor: 11.908
Authors: Erin Baumgartner; Maria Del Carmen Rodriguez Pena; Marie-Lisa Eich; Kristin K Porter; Jeffrey W Nix; Soroush Rais-Bahrami; Jennifer Gordetsky Journal: Hum Pathol Date: 2019-05-07 Impact factor: 3.466